170 related articles for article (PubMed ID: 17972960)
1. Expression of ligands to NKp46 in benign and malignant melanocytes.
Cagnano E; Hershkovitz O; Zilka A; Bar-Ilan A; Golder A; Sion-Vardy N; Bogdanov-Berezovsky A; Mandelboim O; Benharroch D; Porgador A
J Invest Dermatol; 2008 Apr; 128(4):972-9. PubMed ID: 17972960
[TBL] [Abstract][Full Text] [Related]
2. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
3. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
4. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.
Speeckaert R; van Geel N; Vermaelen KV; Lambert J; Van Gele M; Speeckaert MM; Brochez L
Pigment Cell Melanoma Res; 2011 Apr; 24(2):334-44. PubMed ID: 21029398
[TBL] [Abstract][Full Text] [Related]
5. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
Hussein MR; Elsers DA; Fadel SA; Omar AE
J Clin Pathol; 2006 Mar; 59(3):316-24. PubMed ID: 16505286
[TBL] [Abstract][Full Text] [Related]
6. Beta 2 microglobulin expression in normal melanocytes, nevocellular nevi, and malignant melanomas.
Takata M; Hirone T; Matsumura H
J Invest Dermatol; 1989 May; 92(5 Suppl):243S-247S. PubMed ID: 2654298
[TBL] [Abstract][Full Text] [Related]
7. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.
Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V
Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388
[TBL] [Abstract][Full Text] [Related]
8. Premalignant quiescent melanocytic nevi do not express the MHC class I chain-related protein A.
Fuertes MB; Rossi LE; Peralta CM; Cabrera HN; Allevato MA; Zwirner NW
Medicina (B Aires); 2011; 71(4):357-60. PubMed ID: 21893449
[TBL] [Abstract][Full Text] [Related]
9. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
10. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
11. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
Santucci M; Urso C; Giannini A; Bondi R
Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
[TBL] [Abstract][Full Text] [Related]
12. [Intraepidermal distribution patterns of melanocytes in the melanocytic lesions on the sole: proposed criteria for histopathologic diagnosis of plantar malignant melanoma in situ].
Saida T; Yoshida N
Nihon Hifuka Gakkai Zasshi; 1989 Apr; 99(5):553-60. PubMed ID: 2585770
[TBL] [Abstract][Full Text] [Related]
13. Nevi, other than dysplastic and Spitz nevi.
Cochran AJ; Bailly C; Paul E; Dolbeau D
Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
[TBL] [Abstract][Full Text] [Related]
14. A melanoma immune response signature including Human Leukocyte Antigen-E.
Tremante E; Ginebri A; Lo Monaco E; Benassi B; Frascione P; Grammatico P; Cappellacci S; Catricalà C; Arcelli D; Natali PG; Di Filippo F; Mottolese M; Visca P; Benevolo M; Giacomini P
Pigment Cell Melanoma Res; 2014 Jan; 27(1):103-12. PubMed ID: 24011128
[TBL] [Abstract][Full Text] [Related]
15. In vivo confocal microscopic and histopathologic correlations of dermoscopic features in 202 melanocytic lesions.
Pellacani G; Longo C; Malvehy J; Puig S; Carrera C; Segura S; Bassoli S; Seidenari S
Arch Dermatol; 2008 Dec; 144(12):1597-608. PubMed ID: 19075142
[TBL] [Abstract][Full Text] [Related]
16. Tumor progression in the human melanocytic system.
Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
[TBL] [Abstract][Full Text] [Related]
17. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
18. Adhesion molecule profile and malignancy of melanocytic lesions.
Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
20. Rat NKp46 activates natural killer cell cytotoxicity and is associated with FcepsilonRIgamma and CD3zeta.
Westgaard IH; Berg SF; Vaage JT; Wang LL; Yokoyama WM; Dissen E; Fossum S
J Leukoc Biol; 2004 Dec; 76(6):1200-6. PubMed ID: 15356098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
